Survodutide 12 MG

The Dual GLP-1/Glucagon Agonist Peptide is a synthetic 29-amino-acid peptide designed to target both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Primarily researched in the United States and Europe, this peptide is under investigation for its potential in the treatment of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) due to its combined effects on glucose regulation, weight loss, and hepatic metabolism.

Pharmacokinetics and mechanism of action highlights include:

• Binding and activation of GLP-1R and GCGR with an approximate receptor activity ratio of 8:1 (favoring GLP-1R), designed to optimize weight loss and glycemic control without inducing hyperglycemia.
• GLP-1R activation promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and decreases appetite via central nervous system effects, resulting in lowered food intake and postprandial glucose levels.
• GCGR activation increases energy expenditure through stimulation of hepatic glucose production, lipolysis, and amino acid breakdown, contributing to weight reduction and improved lipid profiles.
• Albumin binding via a C18 diacid moiety extends the peptide’s half-life to approximately 109–115 hours, enabling once-weekly subcutaneous administration.
• Clinical studies demonstrate significant reductions in HbA1c (up to 1.5%) and robust weight loss (up to 12.1% of body weight), along with improvements in blood pressure and plasma triglycerides.
• Common adverse effects include gastrointestinal symptoms—such as nausea, vomiting, diarrhea, and constipation—which may be mitigated by gradual dose escalation.
• Ongoing Phase 2 and 3 clinical trials are evaluating its long-term safety and efficacy in obesity, type 2 diabetes, and NASH.

This peptide is supplied exclusively for laboratory research purposes and molecular pharmacology investigations. It is not intended for diagnostic, therapeutic, or clinical use and must not be administered to humans or animals. For Research Use Only.

Product Details:

• Molecular Formula: C192H289N47O61
• Molecular Weight: 4231.7 Da
• Appearance: White to off-white lyophilized powder
• Binding: The fatty diacid moiety enables high albumin binding, prolonging plasma half-life for once-weekly dosing.

This product is intended exclusively for scientific research and laboratory investigation in compliance with applicable regulatory guidelines.